Cargando…

Immunogenicity And Safety Of The 13-Valent Pneumococcal Conjugate Vaccine In Patients With Monoclonal Gammopathy Of Undetermined Significance – Relationship With Selected Immune And Clinical Parameters

PURPOSE: Patients with monoclonal gammopathy of undetermined significance (MGUS) have an increased risk of developing infections. Streptococcus pneumoniae vaccinations are recommended for immunocompromised patients, including patients with lymphoproliferative disorders such as MGUS. The objective of...

Descripción completa

Detalles Bibliográficos
Autores principales: Pasiarski, Marcin, Sosnowska-Pasiarska, Barbara, Grywalska, Ewelina, Stelmach-Gołdyś, Agnieszka, Kowalik, Artur, Góźdź, Stanisław, Roliński, Jacek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790629/
https://www.ncbi.nlm.nih.gov/pubmed/31631993
http://dx.doi.org/10.2147/CIA.S220423
_version_ 1783458811612233728
author Pasiarski, Marcin
Sosnowska-Pasiarska, Barbara
Grywalska, Ewelina
Stelmach-Gołdyś, Agnieszka
Kowalik, Artur
Góźdź, Stanisław
Roliński, Jacek
author_facet Pasiarski, Marcin
Sosnowska-Pasiarska, Barbara
Grywalska, Ewelina
Stelmach-Gołdyś, Agnieszka
Kowalik, Artur
Góźdź, Stanisław
Roliński, Jacek
author_sort Pasiarski, Marcin
collection PubMed
description PURPOSE: Patients with monoclonal gammopathy of undetermined significance (MGUS) have an increased risk of developing infections. Streptococcus pneumoniae vaccinations are recommended for immunocompromised patients, including patients with lymphoproliferative disorders such as MGUS. The objective of the study was to assess the immune response to the 13-valent pneumococcal conjugate vaccine (PCV13) in treatment-naive MGUS patients versus healthy subjects. All study groups were evaluated for the levels of specific pneumococcal antibodies, the levels of IgG and IgG subclasses, and selected peripheral blood lymphocyte subpopulations, including the proportion of plasmablasts before and after immunization. PATIENTS AND METHODS: A total of 22 previously untreated patients with MGUS and 15 healthy age- and sex-matched volunteers were included in the study. All participants were immunized with PCV13 Prevenar13 (Pfizer). The following parameters were assessed: 1) serum-specific pneumococcal antibody titers before and 30 days after vaccination, 2) percentage of plasmablasts, defined as CD19+/IgD−/CD27++, before and 7 days after vaccination, 3) serum total IgG and IgG1, IgG2, IgG3, IgG4 levels before and 30 days after vaccination. RESULTS AND CONCLUSION: PCV13 vaccination in MGUS patients is safe and effectively protects against S. pneumoniae infection. In unvaccinated individuals, vaccination should be carried out as soon as possible after diagnosis. It can protect patients against serious infectious complications, which can contribute to extending the time to progression and transformation into more aggressive diseases. PCV13 vaccination is more effective in MGUS patients with a lower concentration of M protein. Serum M protein concentration in patients diagnosed with MGUS may be a useful predictor of the effectiveness of vaccination.
format Online
Article
Text
id pubmed-6790629
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-67906292019-10-18 Immunogenicity And Safety Of The 13-Valent Pneumococcal Conjugate Vaccine In Patients With Monoclonal Gammopathy Of Undetermined Significance – Relationship With Selected Immune And Clinical Parameters Pasiarski, Marcin Sosnowska-Pasiarska, Barbara Grywalska, Ewelina Stelmach-Gołdyś, Agnieszka Kowalik, Artur Góźdź, Stanisław Roliński, Jacek Clin Interv Aging Original Research PURPOSE: Patients with monoclonal gammopathy of undetermined significance (MGUS) have an increased risk of developing infections. Streptococcus pneumoniae vaccinations are recommended for immunocompromised patients, including patients with lymphoproliferative disorders such as MGUS. The objective of the study was to assess the immune response to the 13-valent pneumococcal conjugate vaccine (PCV13) in treatment-naive MGUS patients versus healthy subjects. All study groups were evaluated for the levels of specific pneumococcal antibodies, the levels of IgG and IgG subclasses, and selected peripheral blood lymphocyte subpopulations, including the proportion of plasmablasts before and after immunization. PATIENTS AND METHODS: A total of 22 previously untreated patients with MGUS and 15 healthy age- and sex-matched volunteers were included in the study. All participants were immunized with PCV13 Prevenar13 (Pfizer). The following parameters were assessed: 1) serum-specific pneumococcal antibody titers before and 30 days after vaccination, 2) percentage of plasmablasts, defined as CD19+/IgD−/CD27++, before and 7 days after vaccination, 3) serum total IgG and IgG1, IgG2, IgG3, IgG4 levels before and 30 days after vaccination. RESULTS AND CONCLUSION: PCV13 vaccination in MGUS patients is safe and effectively protects against S. pneumoniae infection. In unvaccinated individuals, vaccination should be carried out as soon as possible after diagnosis. It can protect patients against serious infectious complications, which can contribute to extending the time to progression and transformation into more aggressive diseases. PCV13 vaccination is more effective in MGUS patients with a lower concentration of M protein. Serum M protein concentration in patients diagnosed with MGUS may be a useful predictor of the effectiveness of vaccination. Dove 2019-10-09 /pmc/articles/PMC6790629/ /pubmed/31631993 http://dx.doi.org/10.2147/CIA.S220423 Text en © 2019 Pasiarski et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Pasiarski, Marcin
Sosnowska-Pasiarska, Barbara
Grywalska, Ewelina
Stelmach-Gołdyś, Agnieszka
Kowalik, Artur
Góźdź, Stanisław
Roliński, Jacek
Immunogenicity And Safety Of The 13-Valent Pneumococcal Conjugate Vaccine In Patients With Monoclonal Gammopathy Of Undetermined Significance – Relationship With Selected Immune And Clinical Parameters
title Immunogenicity And Safety Of The 13-Valent Pneumococcal Conjugate Vaccine In Patients With Monoclonal Gammopathy Of Undetermined Significance – Relationship With Selected Immune And Clinical Parameters
title_full Immunogenicity And Safety Of The 13-Valent Pneumococcal Conjugate Vaccine In Patients With Monoclonal Gammopathy Of Undetermined Significance – Relationship With Selected Immune And Clinical Parameters
title_fullStr Immunogenicity And Safety Of The 13-Valent Pneumococcal Conjugate Vaccine In Patients With Monoclonal Gammopathy Of Undetermined Significance – Relationship With Selected Immune And Clinical Parameters
title_full_unstemmed Immunogenicity And Safety Of The 13-Valent Pneumococcal Conjugate Vaccine In Patients With Monoclonal Gammopathy Of Undetermined Significance – Relationship With Selected Immune And Clinical Parameters
title_short Immunogenicity And Safety Of The 13-Valent Pneumococcal Conjugate Vaccine In Patients With Monoclonal Gammopathy Of Undetermined Significance – Relationship With Selected Immune And Clinical Parameters
title_sort immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in patients with monoclonal gammopathy of undetermined significance – relationship with selected immune and clinical parameters
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790629/
https://www.ncbi.nlm.nih.gov/pubmed/31631993
http://dx.doi.org/10.2147/CIA.S220423
work_keys_str_mv AT pasiarskimarcin immunogenicityandsafetyofthe13valentpneumococcalconjugatevaccineinpatientswithmonoclonalgammopathyofundeterminedsignificancerelationshipwithselectedimmuneandclinicalparameters
AT sosnowskapasiarskabarbara immunogenicityandsafetyofthe13valentpneumococcalconjugatevaccineinpatientswithmonoclonalgammopathyofundeterminedsignificancerelationshipwithselectedimmuneandclinicalparameters
AT grywalskaewelina immunogenicityandsafetyofthe13valentpneumococcalconjugatevaccineinpatientswithmonoclonalgammopathyofundeterminedsignificancerelationshipwithselectedimmuneandclinicalparameters
AT stelmachgołdysagnieszka immunogenicityandsafetyofthe13valentpneumococcalconjugatevaccineinpatientswithmonoclonalgammopathyofundeterminedsignificancerelationshipwithselectedimmuneandclinicalparameters
AT kowalikartur immunogenicityandsafetyofthe13valentpneumococcalconjugatevaccineinpatientswithmonoclonalgammopathyofundeterminedsignificancerelationshipwithselectedimmuneandclinicalparameters
AT gozdzstanisław immunogenicityandsafetyofthe13valentpneumococcalconjugatevaccineinpatientswithmonoclonalgammopathyofundeterminedsignificancerelationshipwithselectedimmuneandclinicalparameters
AT rolinskijacek immunogenicityandsafetyofthe13valentpneumococcalconjugatevaccineinpatientswithmonoclonalgammopathyofundeterminedsignificancerelationshipwithselectedimmuneandclinicalparameters